TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
NCT ID: NCT04168723
Last Updated: 2020-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
64 participants
INTERVENTIONAL
2019-11-11
2020-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The planned enrollment is approximately 64 subjects randomized in a ratio of 1:1 to 2main groups. Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
NCT04795479
Study Evaluating the Effects of MOA-728 on Cardiac Repolarization in Healthy Subjects
NCT00434395
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
NCT01812538
Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
NCT03012828
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
NCT05660720
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Phase 1, single-center, double-blind, randomized, placebo- and positive controlled, double-dummy, parallel-group, repeated-dose study with a nested cross-over comparison between moxifloxacin and placebo to evaluate the effect of MD1003 on cardiac repolarization in healthy adult subjects.
A total of 64 subjects will be enrolled in the clinical study according to the inclusion/exclusion criteria. The study consists of two main groups with 32 subjects per dose group. All subjects will receive placebo for MD1003 on Day -1. Subjects in Group A will receive MD1003 (biotin) 1200 mg and placebo for moxifloxacin on Day 1, MD1003 (biotin) 1200 mg from Day 2 through Day 8 and placebo for moxifloxacin on Day 9. Subjects in Group B will be further randomized to Subgroup B1 (16 subjects) receiving moxifloxacin 400 mg and placebo for MD1003 on Day 1, placebo for MD1003 from Day 2 through Day 8 and placebo for moxifloxacin on Day 9. Subgroup B2 (16 subjects) will receive placebo for moxifloxacin and placebo for MD1003 on Day 1, placebo for MD1003 from Day 2 through Day 8 and moxifloxacin 400 mg on Day 9.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A-MD1003
Group A=32 subjects Placebo for MD1003 on Day -1. Daily dose of 1200 mg of MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Day 9
MD1003
Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
Placebo for MD1003
Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
Placebo for moxifloxacin
Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Group B-Moxifloxacin
Subjects in Group B will be further randomized to Subgroups B1 and B2 in a ratio of 1:1.
Subgroup B1: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Moxifloxacin 400 mg on Day 1 and Placebo for moxifloxacin on Day 9 Subgroup B2: 16 subjects Placebo for MD1003 on Day -1 Placebo for MD1003 from Day 1 to Day 8 Placebo for moxifloxacin on Day 1 and Moxifloxacin 400 mg on Day 9
Moxifloxacin 400mg
Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
Placebo for MD1003
Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
Placebo for moxifloxacin
Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MD1003
Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
Moxifloxacin 400mg
Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
Placebo for MD1003
Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
Placebo for moxifloxacin
Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.
3. Female subjects of childbearing potential must not be planning to become pregnant, must not be breastfeeding, and must have a negative serum pregnancy test at Screening and negative urine pregnancy test on Day-2.
4. Sexually active female subjects of childbearing potential (i.e. women who are not post-menopausal \[12 months of spontaneous amenorrhea without an alternative medical cause and follicle stimulating hormone (FSH) levels in the post-menopausal range for the laboratory involved\] or who have not had a documented hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) and all male subjects (who have not been surgically sterilized by documented vasectomy) must agree to use highly effective methods of contraception during the study and for 8 weeks after the last dose of study drug. Please refer to Section 5.4.4 for acceptable methods of contraception.
5. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the screening.
6. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive, at the Screening Visit.
7. Healthy adult subjects with suitable veins for cannulation.
8. Healthy, determined by pre-study medical evaluation (medical history, renal function, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations).
9. Supine vital signs should be within the normal range at Screening and Day -2:
1. oral body temperature between 35.0°C - 37.5°C;
2. systolic BP, 90 - 140 mm Hg;
3. diastolic BP, 40 - 90 mm Hg;
4. pulse rate, 40 - 100 bpm.
10. Subjects should have serum potassium, calcium, and magnesium levels within the normal range at Screening and at admission on Day -2 (morning in fasted condition).
11. Subjects should fulfil the following ECG parameters criteria at Screening and Day -2:
1. Normal sinus rhythm (HR between 40 beats per minute \[bpm\] and 100 bpm, inclusive);
2. Fridericia QTc interval corrected (QTcF)≤ 450 msec;
3. QRS interval ≤110 msec; and confirmed by manual over-read if \> 110 msec;
4. PR interval ≤220 msec.
Exclusion Criteria
2. Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs.
3. Subject has any concurrent disease or condition that, in the opinion of the Principal Investigator, would make the subject unsuitable for participation in the clinical study.
4. History or presence of:
1. risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, or family history of Long QT Syndrome);
2. sick sinus syndrome, Mobitz 2second, or third-degree atrioventricular block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval QTc\>450 male/470 female), or conduction abnormalities;
3. repeated or frequent syncope or vasovagal episodes;
4. hypertension, angina, bradycardia, or severe peripheral arterial circulatory disorders.
5. Subjects with serum creatinine clearance below 90 mL/min.
6. Subject has history of alcohol and/or illicit drug abuse within 2 years prior to the first dose of study drug.
7. Subject has positive test for Hepatitis B surface antigen, Hepatitis C antibody or human immunodeficiency virus antibody at the screening visit.
8. Subject has positive urine drug (e.g., cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids), alcohol or cotinine test at the Screening Visit or Day -2. Consumption of alcohol and alcohol-containing foods, medications or beverages 48 hours prior to the screening visit.
9. Female subjects are breastfeeding or female subjects with a positive serum pregnancy test at the Screening Visit or positive urine pregnancy test on Day -2.
10. Has had surgery or any medical condition which may affect the absorption, distribution, metabolism, or elimination of the study drugs within 6 months prior to the first dose, in the opinion of the Principal Investigator.
11. Plasma donation within 7 days prior to the first dose of study drug.
12. Subject has donated \> 500 mL blood or blood products within 2 months (56 days) prior to admission.
13. Subject is unwilling to avoid consumption of coffee and caffeine containing beverages from 48 hours prior to admission until discharge from the clinical site.
14. Use of any prescription or over-the-counter medication including antacids, herbal remedies, or vitamin or nutritional supplements (especially those containing biotin, magnesium, aluminum, iron, or zinc), excluding contraceptive pill, and intermittent use of paracetamol, ibuprofen, or acetylic salicylic acid within 14 days prior to Screening and throughout the study, unless approved by both the Investigator and the Sponsor.
15. Subject has used an investigational drug, or device within 3 months or 5 half-lives of the investigational drug (whichever is longer) prior to Screening.
16. Participation in a previous clinical trial where subject received MD1003.
17. Subject has been on a diet incompatible with the on study diet (including an extreme diet which resulted in a significant weight change for whatever reason), in the opinion of the Principal Investigator, within the 28 days prior to the first dose of study drug, and throughout the study.
18. Subject is unwilling to abstain from vigorous exercise from 48 hours prior to admission until the End of Study Visit.
19. Subject has a history of hypersensitivity to the study drug or any of the excipients (incl. lactose), or to medicinal products with similar chemical structures.
20. Subject is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.
21. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent).
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
ERT: Clinical Trial Technology Solutions
OTHER
MedDay Pharmaceuticals SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muna Albayaty, MD
Role: PRINCIPAL_INVESTIGATOR
Parexel Early Phase Clinical Unit London,Northwick Park Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parexel Early Phase Clinical Unit London
London, Middlesex, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MD1003CT2019-04TQT2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.